461-34-7

Basic information

• Product Name: 4,4,4-Trifluorobutyramide
• Synonyms: 4,4,4-Trifluorobutanamide;4,4,4-Trifluorobutyramide
• CAS NO: 461-34-7
• Molecular Formula: C4H6F3NO
• Molecular Weight: 141.0917496
• Mol File: 461-34-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,4,4-Trifluorobutyramide(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4,4-Trifluorobutyramide(461-34-7)
• EPA Substance Registry System: 4,4,4-Trifluorobutyramide(461-34-7)

Safety Data

• Hazardous Substances Data: 461-34-7(Hazardous Substances Data)

Usage

General Description

4,4,4-Trifluorobutyramide is a chemical compound that consists of a four carbon chain with an amide functional group and three fluorine atoms attached to the third carbon. It is often used as a building block in the synthesis of various pharmaceuticals and agrochemicals. 4,4,4-Trifluorobutyramide is known for its high stability and low reactivity, making it a valuable intermediate in organic synthesis. Its distinctive fluorine atoms also make it an important tool in medicinal chemistry, as fluorinated molecules tend to have unique pharmacokinetic and pharmacodynamic properties. Additionally, 4,4,4-Trifluorobutyramide has potential applications in the field of materials science, particularly as a component in the development of advanced polymers and coatings due to its fluorinated nature.

Upstream product

• 75-63-8 Bromotrifluoromethane 
• 79-06-1 2-propenamide 
• 406-91-7 4,4,4-trifluorobutanoyl chloride 
• 406-93-9 4,4,4-trifluorobutyric acid 

Downstream Products

• 690-95-9 4,4,4-trifluorobutanenitrile 
• 819-46-5 4,4,4-trifluorobutan-1-amine 

Relevant articles and documents

Method for preparing fluoroalkane substituted compound by reducing halogenated fluoroalkane and olefin through metal elementary substance

The invention discloses a method for preparing a fluoroalkane substituted compound, which comprises the steps of taking a compound containing carbon-carbon double bonds and halogenated fluoroalkane as raw materials, taking a metal elementary substance as a reducing agent, taking a substance containing active protons as a hydrogen source, and carrying out an addition reaction to prepare a compound which is simultaneously substituted by hydrogen and fluoroalkyl, thereby obtaining the fluoroalkane substituted compound. According to the method, the metal elementary substance is used as the reducing agent for the first time, the compound containing active hydrogen is used as the hydrogen source, one hydrogen atom and one fluoroalkyl group are introduced to the two ends of olefin respectively, only one-step reaction is needed, the reaction process conditions are mild, the reaction raw materials are cheap and easy to obtain, the cost is low, and all reaction reagents are green and environmentally friendly; and the reaction substrate has strong applicability, can participate in the reaction as long as carbon-carbon double bonds exist in the structure, and is not influenced by the types of substituent groups on carbon atoms of the double bonds, and the yield of the product is good.

FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF

The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. The present invention relates to a compound represented by the following formula: wherein each symbol is as defined in the specification, or a salt thereof.

Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-indolecarboxamides: Identification of 4--1-methylindol-3-yl>methyl>-3-methoxy-N-benzamide, ...

The continued exploration of a series of 3-(arylmethyl)-1H-indole-5-carboxamides by the introduction of fluorinated amide substituents has resulted in the discovery of 4--1-methylindol-3-yl>methyl>-3-methoxy-N-benzamide (38p, ZENECA ZD 3523), which has been chosen for clinical evaluation.This compound exhibited a Ki of 0.42 nM for displacement of LTD4 on guinea pig lung membranes, a pKB of 10.13 +/- 0.14 versus LTE4 on guinea pig trachea, and an oral ED50 of 1.14 μmol/kg opposite LTD4-induced bronchoconstriction in guinea pigs.The R enantiomer was found to be modestly more potent than the S enantiomer 38o.Modification of the amide substituent to afford achiral compounds was unsuccessful in achieving comparable levels of activity.Profiling of 38p opposite a variety of functional assays has demonstrated the selectivity of this compound as a leukotriene receptor antagonist.The enantioselective synthesis of 38p, which employed a diastereoselective alkylation of (4R,5S)-3-(1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazolidinone (27) as the key step to establish the chirality of the amide substituent, provided an efficient route for generating 38p in >99percent enantiomeric purity.